HDAC-2 overexpression has been associated with poor prognosis in patients with gastric [41], colorectal [42], hepatocellular [34,47] and prostate carcinoma (especially Gleason score 7 cases) [35], while it has been connected with prolonged survival in invasive breast carcinoma cases [29]. The gene discussed is HDAC2; the disease is prostate carcinoma.